Abcellera Biologics (ABCL) has had the highest return since July 25, 2026 by a mid-cap US stock, returning 110%.
| ASSET | % RETURN |
|---|---|
Abcellera Biologics (ABCL) | 109.99% |
Heartflow, Inc Common Stock (HTFL) | 95.18% |
Amylyx Pharmaceuticals (AMLX) | 87.78% |
Hyperliquid Strategies Inc Common Stock (PURR) | 82.55% |
NIQ Global Intelligence (NIQ) | 76.96% |
Appian (APPN) | 73.09% |
Standard Nuclear (STDN) | 71.95% |
Wix (WIX) | 65.57% |
Caris Life Sciences, Inc Common Stock (CAI) | 63.35% |
Uipath (PATH) | 62.78% |
Figs (FIGS) | 61.13% |
Iovance Biotherapeutics (IOVA) | 59.56% |
Alpha Metallurgical Resources (AMR) | 58.27% |
Zhong Yang Financial Group Limited Ordinary Shares (TOP) | 57.09% |
Pulse Biosciences (PLSE) | 57.05% |
Aura Minerals Inc Common Shares (AUGO) | 55.65% |
Zeta Global (ZETA) | 54.95% |
Abercrombie & Fitch (ANF) | 54.6% |
Rumble (RUM) | 53.77% |
Braze (BRZE) | 53.26% |
Intapp (INTA) | 53.01% |
Neutron Holdings, Inc Common Stock (LIME) | 51.76% |
Twist Bioscience (TWST) | 51.21% |
Workiva (WK) | 47.23% |
Blackbaud (BLKB) | 47.2% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.